Ligand Licenses DARA Program to Retrophin
Ligand to Present at the BIO CEO and Investor Conference on February 13
Ligand Reports Fourth Quarter and Full Year 2011 Financial Results
Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development
Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings
Ligand to Report Fourth Quarter Results on February 7
Ligand to Present at the Biotech Showcase Conference on January 10th
Ligand Enters into Platform Captisol® License and Supply Agreements with Lilly
Ligand Announces Positive Preclinical Data on Small-Molecule GCSF Receptor Agonist at the 53rd Annual Meeting of the American Society of Hematology
Ligand to Present at the Oppenheimer Healthcare Conference on December 14
Save-the-Date: Ligand Hosting Promacta Panel Discussion on November 7
Ligand to Report Third Quarter Results on November 8
Ligand Enters into Platform Captisol® License Agreement with SAGE Therapeutics
Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn®
